1 LETTER

~

2	
3	The contribution of common regulatory and protein-coding TYR variants in the
4	genetic architecture of albinism
5	
6	Vincent Michaud ^{1,2} , Eulalie Lasseaux ¹ , David J. Green ³ , Dave T. Gerrard, ³ Claudio
7	Plaisant ¹ , UK Biobank Eye and Vision Consortium, Tomas Fitzgerald ⁴ , Ewan Birney ⁴ ,
8	Benoît Arveiler ^{1,2} , Graeme C. Black ^{3,5} , Panagiotis I. Sergouniotis ^{3,5,6}
9	
10	¹ Department of Medical Genetics, University Hospital of Bordeaux, Bordeaux,
11	France.
12 13	² INSERM U1211, Rare Diseases, Genetics and Metabolism, University of Bordeaux,
14	Bordeaux, France.
15	
16	³ Division of Evolution, Infection & Genomics, School of Biological Sciences, Faculty
17	of Biology, Medicines and Health, University of Manchester, Manchester, UK.
18 19	⁴ European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-
20	EBI), Wellcome Genome Campus, Cambridge, UK.
21	
22	⁵ Manchester Centre for Genomic Medicine, Saint Mary's Hospital, Manchester
23	University NHS Foundation Trust, Manchester, UK.
24	
25	^o Manchester Royal Eye Hospital, Manchester University NHS Foundation Trust,
26	Manchester, UK.
27	

These authors contributed equally: VM, EL, DJG 28 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 29 These authors contributed equally: BA, GCB
- 30 Corresponding authors: BA, GCB, PIS.

ABSTRACT 31

32 Genetic diseases have been historically segregated into rare Mendelian and common complex conditions.^{1,2} Large-scale studies using genome sequencing are 33 34 eroding this distinction and are gradually unmasking the underlying complexity of human traits.³⁻⁸ Aiming to gain insights into the genetic architecture of rare 35 36 recessive disorders, we studied a cohort of 1,313 individuals with albinism, an 37 archetypal Mendelian condition. We investigated the contribution of protein-coding 38 and regulatory variants both rare and common. We focused on TYR, the gene 39 encoding tyrosinase, and found that a high-frequency promoter variant, TYR c.-40 301C>T [rs4547091], modulates the penetrance of a prevalent, disease-associated 41 missense change, TYR c.1205G>A [rs1126809]. We also found that homozygosity 42 for a haplotype formed by three common, functionally-relevant variants, TYR c.[-43 301C:575C>A:1205G>A], is associated with a high probability of receiving an 44 albinism diagnosis (OR>82). This genotype is also associated with reduced visual 45 acuity and increased central retinal thickness in UK Biobank participants. Finally, 46 we report how the combined analysis of rare and common variants increases diagnostic yield and informs genetic counselling in families with albinism. 47 48

49 **MAIN**

50 There is abundant evidence supporting the view that rare genetic diseases are 51 caused by rare, high-impact variants in individual genes. However, for most known 52 rare disorders, it is not possible to identify such pathogenic changes in every affected proband, leaving significant diagnostic and knowledge gaps.⁹⁻¹¹ In recent 53 54 years, the emergence of comprehensive rare disease and population-based resources that link genomic and phenotypic data (e.g. UK Biobank¹², Genomics 55 England 100,000 Genomes Project¹³) has offered unprecedented opportunities for 56 genetic discovery. Through integrative analysis of these datasets, we can now 57 58 achieve line-of-sight for uncovering complex molecular explanations in people with rare disorders who have hitherto remained undiagnosable. 59 60 61 Albinism, a rare condition characterised by decreased ocular pigmentation and altered visual system organisation¹⁴, had a pivotal role in the study of human 62 genetics tracing back to the early 20th century.^{15,16} At least 20 genes are now known 63 to be associated with this disorder and the current diagnostic yield of genetic 64 testing in affected cohorts approaches 75%.¹⁷⁻¹⁹ Most people with a molecular 65 diagnosis of albinism carry biallelic variants in TYR, the gene encoding the rate-66 67 limiting enzyme of melanin biosynthesis²⁰. Building on recent work^{17,21}, we sought to 68 increase our understanding of the genetic complexity of this archetypal disorder. 69

A cohort of 1208 people with albinism underwent testing of ≤19 albinism-related
genes; these individuals were not known to be related and had predominantly
European ancestries (Supplementary Table 1). A further 105 probands with albinism

- 73 were identified in the Genomics England 100,000 Genomes Project dataset¹³. A
- ⁷⁴ 'control' cohort of 29,497 unrelated individuals that had no recorded
- 75 diagnosis/features of albinism was also identified in this resource (Fig.1,
- 76 Supplementary Table 2, Methods).
- 77

Figure 1. Outline of the case-control study design



A case-control analysis was performed to gain insights into the contribution of protein-coding and regulatory variation, at the common and rare ends of the allele-frequency spectrum, in albinism. The majority of participants in the 'case' cohort (1208/1313) were identified through the database of the University Hospital of Bordeaux Molecular Genetics Laboratory, France. All these probands had at least one key ocular feature of albinism, *i.e.* nystagmus or prominent foveal hypoplasia. The remaining 105/1313 cases were identified through the Genomics England 100,000 Genomes Project dataset and had a diagnosis of albinism or a phenotype deemed consistent with partial/ocular albinism. The 'control' cohort included 29,497 unrelated individuals from the Genomics England 100,000 Genomes Project dataset, none of whom had a recorded diagnosis of albinism.

Genotypes that include selected *TYR* haplotypes in homozygous state were studied. Haplotypes of interest were defined as those formed by combinations of *TYR* variants that are predicted to be functionally relevant; three variants met the pre-determined criteria set for regulatory (*TYR* c.-301C>T) and common protein-coding (*TYR* c.575C>A and c.1205G>A) variants. The associated haplotypic blocks were analysed further using logistic regression (see Methods).

100K GP, Genomics England 100,000 Genomes Project; eQTLs, expression quantitative trait loci; MAF, minor allele frequency; CADD, Combined Annotation Dependent Depletion score; HGMD, Human Gene Mutation Database v2021.2. TYR variant numbering is based on the transcript with the following identifiers: NM_000372.5 and ENST00000263321.6.

78

79	To gain insights into the contribution of common variants to the genetic architecture
80	of albinism, we studied the impact of protein-coding changes that have minor allele
81	frequency [MAF] \geq 1% and are predicted by a computational algorithm to be
82	functionally relevant (CADD score ²² \geq 20). For <i>TYR</i> , two such variants were identified:
83	c.575C>A (p.Ser192Tyr) [rs1042602] and c.1205G>A (p.Arg402Gln) [rs1126809].
84	Multiple associations have been recorded for these two changes including skin/hair
85	pigmentation (for both variants), macular thickness (for c.575C>A) and iris colour
86	(for c.1205G>A). ²³ Furthermore, each of these changes has been shown to decrease
87	TYR enzymatic activity in vitro. ^{24,25} Importantly, there is evidence suggesting that
88	c.1205G>A is acting as a hypomorphic variant and is causing a mild form of
89	albinism when in compound heterozygous state with a complete loss-of-function
90	TYR mutation. ²⁶ It is also noted that the MAF of this variant in European populations
91	is around 27% and that multiple unaffected homozygous individuals have been
92	reported (including >2,000 people in the control subset of the Genome Aggregation
93	Database [gnomAD] v2.1.1) ²⁷ .

94

95 To gain insights into the contribution of regulatory variants, we studied the impact of 96 changes that alter TYR regulatory elements (i.e. the TYR promoter or ENCODE-97 listed enhancers)²⁸ and affect *TYR* gene expression (*i.e.* they are known *TYR* 98 expression quantitative trait loci [eQTL]). One such variant was identified, c.-301C>T [rs4547091], a fetal retinal pigment epithelium (RPE) selective eQTL²⁹. This change is 99

known to alter a binding site for the transcription factor *OTX2* in the *TYR* promoter,
and the reference allele (c.-301C) has been shown to lead to a remarkable decrease
in promoter activity *in vitro*³⁰.

103

Focusing on individual sequence alterations without consideration for variant 104 interactions and/or patterns of linkage disequilibrium can lead to masking of 105 106 complex underlying mechanisms. To overcome this pitfall, we avoided an 107 independent analysis of each of the TYR c.-301C>T, c.575C>A and c.1205G>A 108 changes and instead studied the haplotype blocks that they form. Eight possible haplotypes $[2^3]$ and 36 possible haplotype pairs $[2^{3-1} \times (2^3+1)]$ may be encountered. 109 110 We focused only on the 8 haplotype pairs that include homozygous alleles (Fig.2A) 111 for two reasons: (1) in homozygous individuals, the underlying haplotypes can be 112 unambiguously determined, even in cases where segregation/phasing data are 113 unavailable; (2) in autosomal recessive disorders like TYR-related albinism, 114 phenotypic abnormalities are the result of the combined effect of two alleles; by 115 analyzing only homozygous cases, the effect of a specific haplotype can be isolated 116 and estimated with greater precision.

117

We used Firth regression analysis^{31,32} to study how *TYR* haplotypes in homozygous state affect the risk of albinism (i.e. the probability of having a diagnosis of albinism). This increasingly recognised logistic regression approach has been designed to handle small, imbalanced datasets (which are common in studies of rare conditions) and allows for adjustment of key covariates (which is not possible in contingency table methods) (Fig.1, Methods). The results are shown in Fig.2B and

- 124 Supplementary Table 3. This analysis identified a number of pertinent points that
- 125 are discussed below.

126



Figure 2. Common *TYR* variants form haplotypes that affect risk of albinism and visual performance.

a. The *TYR* haplotypes that were studied are shown. The reference allele of the *TYR* c.-301C>T [rs4547091] promoter variant reduces gene expression and is shown as C (\downarrow); the non-reference allele increases gene expression and is shown as T (\uparrow). The reference alleles of the c.575C>A (p.Ser192Tyr) [rs1042602] and the c.1205G>A (p.Arg402Gln) [rs1126809] missense variants are highlighted in green font while the non-reference alleles are highlighted in red font. As no homozygotes for the *TYR* [-301T;575A;1205A] and [-301T;575A;1205G] haplotypes were detected, these combinations are highlighted in grey font.

b. Risk of albinism (i.e. probability of receiving a diagnosis of albinism) in people carrying selected *TYR* haplotypes in homozygous state. Odds ratio >1 suggests an increased risk while odds ratio <1 suggests a decreased risk. Further information including numeric data can be found in Supplementary Table 3.

c. Visual acuity in UK Biobank participants carrying selected *TYR* haplotypes in homozygous state. Vision near 0.0 LogMAR is considered normal while vision >0.5 LogMAR is considered moderate/severe visual impairment. The Kruskal-Wallis p-value was 8×10^{-11} . Further information including numeric data can be found in Supplementary Table 5.

127	We found that the penetrance of the hypomorphic TYR c.1205G>A variant ²⁶ is
128	modulated by the TYR c301C>T promoter change. When c.1205G>A is
129	encountered in a homozygous state and in combination with the c301C allele of
130	the promoter variant (which reduces TYR expression), the risk of albinism is high
131	(OR>24; see [C;A;A] and [C;C;A] in Fig.2B). In contrast, homozygosity for
132	c.1205G>A combined with the c301T allele (which increases TYR expression) has
133	a protective effect (OR<0.7; see [T;C;A] in Fig.2B). This observation is in keeping
134	with previous studies suggesting that penetrance can be modified by the joint
135	functional effects of regulatory and protein-coding variants. ³³ We here provide a key
136	illustration of this mechanism in the context of a recessively-acting hypomorphic
137	variant.
138	
139	Alongside this, we found that homozygosity for the TYR c301C>T promoter variant
140	protects against albinism (OR 0.3-0.7; see [T;C;A] and [T;C;G] in Fig.2B). Notably,
141	the allele frequency of the protective c301T allele, approaches 80% in people of
142	African ancestries and is around 40% in people of European ancestries ²⁷ (see
143	Supplementary Fig.1 for the geographical distribution of the associated
144	variants/haplotypes). It can be speculated that variation in this TYR promoter
145	position partly accounts for the relatively low prevalence of TYR-related albinism in
146	people of African ancestries (Supplementary Table 4).
147	
148	Our findings also highlight that homozygosity for the haplotype formed by the c
149	301C allele of the promoter variant (which reduces TYR expression) and the non-
150	reference alleles of the two common missense changes, c.575C>A and c.1205G>A,

- 151 is associated with a significant increase in the risk of albinism (OR >82; see [C;A;A]
- 152 in Fig.2B). This haplotype is present in ~1% of people with European ancestries in
- 153 the 1000 Genomes Project (phase 3)³⁴, and the associated risk of albinism is
- 154 comparable to that of a loss-of-function Mendelian mutation.
- 155
- 156 When the TYR c.[-301C;575A;1205A] and c.[-301C;575C;1205A] haplotypes
- 157 (corresponding to [C;A;A] and [C;C;A] in Fig.2B) were factored in as Mendelian
- 158 variants in a clinical-grade analysis of the case cohort, the diagnostic yield
- 159 increased from 57% (692/1208) to 76% (916/1208) (Figure 3). It is noted that current
- 160 genetic laboratory pipelines are generally suboptimally set up to identify these
- 161 complex high-risk haplotypes, especially when filtering is based on the rarity of
- 162 individual variants.
- 163
- 164

Figure 3. High level molecular diagnoses in 1208 probands from the University Hospital of Bordeaux albinism cohort.



It was not possible to detect a molecular diagnosis in 24% of cases ("unknown" category). The following genes were implicated in the remaining probands: *TYR* (34%), *OCA2* (19%), *SLC45A2* (8%), *GPR143* (5%), Hermansky-Pudlak syndrome (HPS) related genes (5%), *SLC24A5* (2%), other albinismrelated genes (3%). A significant subset of cases with *TYR*-related albinism were found/presumed to carry either the *TYR* c.[-301C;575A;1205A] or the *TYR* c.[-301C;575C;1205A] haplotype (15% in heterozygous state ["*TYR* het haplotype" category]; 3% in homozygous state ["*TYR* hom haplotype" category]). Further information including a list with all molecular diagnoses can be found in Supplementary Table 1.

165 We subsequently studied the impact of the TYR c.[-301C;575A;1205A] haplotype 166 (corresponding to [C;A;A] in Fig.2B) in UK Biobank participants. We found that 167 people who were homozygous for this haplotype had, on average, reduced visual acuity (mean LogMAR vision 0.10; Kruskal-Wallis p-value 8 x 10⁻¹¹ with all pairwise 168 169 comparisons involving [C:A:A] being statistically significant; Fig.2C and Supplementary Table 5). As visual acuity is a quantitative endophenotype of 170 171 albinism, this finding provides additional evidence supporting the functional significance of this complex haplotype. A similar trend was noted when central 172 retinal thickness, another albinism endophenotype, was assessed (Kruskal-Wallis p-173 value $< 2 \times 10^{-16}$; Supplementary Fig.2 and Supplementary Table 6). We expect that 174 175 future studies analysing visual function and ocular structure in this group of 176 homozygous individuals will provide key insights into the elusive link between RPE melanin synthesis and visual system organisation.³⁵ Furthermore, we anticipate that 177 178 the study of cellular models specific to these homozygous cases (e.g. human 179 induced pluripotent stem cell-derived RPE) will advance our understanding of the molecular pathology of albinism. 180

181

Lastly, we quantified the risk of albinism associated with combinations of rare and common variants. For each study participant, we estimated two key contributors to an individual's risk. First, we counted the number of rare, presumed Mendelian variants in albinism-related genes; single nucleotide variants that have MAF<1% and are labelled as disease-causing (DM) in the Human Gene Mutation Database (HGMD) v2021.2³⁶ were considered. Subsequently, we counted the number of common "risk genotypes" in *TYR* (*i.e.* c.-301C, c.575A and/or c.1205A in

heterozygous state). We found that the presence of >4 common *TYR* risk genotypes confers an increased risk of albinism even in the absence of a rare, HGMD-listed variant (OR>3.6; Table 1). We also found that, when a single heterozygous HGMDlisted variant co-occurs with >1 common *TYR* risk genotype, the risk of albinism is increased (OR>4.2 for rare variants in any albinism-related gene, OR>1.2 for rare variants in *TYR;* Table 1). These observations provide a basis for more precise genetic counseling in families with albinism.

196

197 One potential limitation of this study is our inability to stringently match the albinism 198 cases with the unaffected controls, especially in terms of recent ancestry (which can 199 be correlated with skin pigmentation). Although ancestry was included as a 200 parameter in our regression model, this analysis was imperfect as it was not possible to reliably assign genetic ancestry to most albinism cases. It is known that 201 202 inability to fully account for differences in ancestral background between cases and controls can lead to false-positive association signals.³⁷ We used a combination of 203 204 orthogonal approaches to evaluate the robustness and generalisability of our 205 findings. First, we used 35 presumed neutral single-nucleotide variants to calculate the genomic inflation factor lambda (λ GC)^{38,39}; λ_{median} was found to be 1.04, in 206 207 keeping with limited confounding by ancestry (Supplementary Table 7). 208 Subsequently, we performed targeted sub-analyses of the available cohorts; the results of three focused case-control studies supported our key findings and 209 210 increased confidence in the validity of the detected associations (Supplementary 211 Figure 3 and Supplementary Tables 8-10).

212

213	In conclusion, we have shown that a significant proportion of albinism risk arises
214	from genetic susceptibility linked to common variants. Furthermore, our findings
215	suggest that rare and common protein-coding variation in TYR should be
216	considered in the context of regulatory haplotypes. The concepts discussed here
217	are highly likely to be relevant to the understanding of other rare disorders, and
218	haplotype-based approaches are expected to narrow the diagnostic gap for
219	significant numbers of patients. Future work will embrace more diverse populations
220	and focus on integrating both common and rare variants (including single-
221	nucleotide and copy-number changes) into a single genetic risk score at scale.
222	

ONLINE METHODS 223

224

225 Cohort characteristics and genotyping

226 University Hospital of Bordeaux albinism cohort: Individuals with albinism were identified through the 227 database of the University Hospital of Bordeaux Molecular Genetics Laboratory, France. This is a 228 national reference laboratory that has been performing genetic testing for albinism since 2003 and 229 has been receiving samples from individuals predominantly based in France (or French-administered 230 overseas territories). Information on the dermatological and ophthalmological phenotypes was 231 available and all people included in the study had at least one of the key ocular features of albinism, 232 *i.e.* nystagmus or absence of a foveal pit (prominent foveal hypoplasia). No pre-screening based on 233 genotype was undertaken and only individuals who were not knowingly related were included. 234 235 Genetic testing, bioinformatic analyses, and clinical interpretation were performed as previously 236 described.^{17,26} Briefly, most participants had gene-panel testing of 19 genes associated with albinism 237 (TYR, OCA2, TYRP1, SLC45A2, SLC24A5, C10ORF11, GPR143, HPS 1 to 10, LYST, SLC38A8) 238 using IonTorrent platforms. High-resolution array-CGH (comparative genomic hybridization) was also 239 used to detect copy number variants in these 19 genes. All genetic changes of interest were 240 confirmed with an alternative method (e.g. Sanger sequencing or quantitative PCR). Clinical 241 interpretation of variants was performed using criteria consistent with the 2015 American College of 242 Medical Genetics and Genomics (ACMG) best practice guidelines⁴⁰. Generally, variants with MAF 243 \geq 1% in large publicly available datasets (e.g. gnomAD²⁷) were considered unlikely to be disease-244 causing. We note that the genetic findings in a subset of this cohort (70%; 845/1208) have been 245 partly reported in a previous publication¹⁷ (see Supplementary Table 1 for further information). 246 247 Due to the limited number of genes screened in this cohort, it was not possible to reliably assess 248 genetic ancestry and to objectively assign individuals to ancestry groups. Attempting to mitigate this, 249 we processed available data on self-identified ethnicity that were collected through questionnaires. 250 Responses were inspected and stratification into five broad continental groups (European, African, 251 Admixed American, East Asian, South Asian) was performed.

253 Informed consent was obtained from all participants or their parents in the case of minors. The study 254 was approved by the relevant local ethics committee (Comité de Protection des Personnes Sud-255 Ouest et Outre Mer III, Bordeaux, France) and all investigations were conducted in accordance with 256 the tenets of the Declaration of Helsinki. 257 258 Genomics England 100,000 Genomes Project cohort: Clinical and genomic data from the Genomics 259 England 100,000 Genomes Project were accessed through a secure Research Environment that is 260 available to registered users. This dataset was collected as part of a national genome sequencing 261 initiative.⁴¹ Enrolment was coordinated by Genomics England Limited and participants were recruited 262 mainly at National Health Service (NHS) Hospitals in the UK.¹³ Clinical information was recorded in 263 Human Phenotype Ontology (HPO)⁴² terms and International Classification of Diseases (ICD) codes. 264 Genome sequencing was performed in DNA samples from 78,195 individuals using Illumina HiSeq X 265 systems (150 base-pair paired-end format). Reads were aligned using the iSAAC Aligner 266 v03.16.02.19 and small variants were called using Starling v2.4.7.43 Aggregation of single-sample 267 gVCFs was performed using the Illumina software gVCF genotyper v2019.02.29; 268 normalisation/decomposition was implemented by vt version 0.57721⁴⁴. The multi-sample VCF was 269 then split into 1,371 roughly equal chunks to allow faster processing and the loci of interest were 270 queried using bcftools v1.9⁴⁵ (see https://research-help.genomicsengland.co.uk/display/GERE/ for 271 further information). Only variants that passed all provided site quality control criteria were 272 processed. In addition, we filtered out genotypes with: genotype score <20; read depth <10; allele 273 balance <0.2 and >0.8 for heterozygotes; allele balance >0.1 or <0.9 for homozygotes (reference and 274 alternate, respectively). Genomic annotation was performed using Ensembl VEP⁴⁶; one additional 275 annotation was included - presence of a variant in HGMD v2021.2³⁶ with a "disease-causing" (DM) 276 label. 277 278 Ancestry inference was performed in this cohort using principal component analysis. Data from the 279 1000 genomes project (phase 3) dataset⁴¹ was used and five broad super-populations were 280 projected (European, African, Admixed American, East Asian, South Asian) (further information on 281 this can be found online at https://research-282 help.genomicsengland.co.uk/display/GERE/Ancestry+inference).

283 284	We focused on a pro-determined subset of the Conomics England 100,000 Conomes Project
204	we locused on a pre-determined subset of the denomics England 100,000 denomes Project
285	dataset that includes only unrelated probands (n=29,602). 105 of these individuals had a diagnosis of
286	albinism, <i>i.e.</i> the ICD-10 term "Albinism" [E70.3] and/or the HPO terms "Albinism" [HP:0001022],
287	"Partial albinism" [HP:0007443] or "Ocular albinism" [HP:0001107] were assigned. Together with the
288	University Hospital of Bordeaux cases, these 105 probands formed the 'case' cohort (for the
289	albinism risk analysis). The remaining 29,497 probands had no recorded diagnosis or phenotypic
290	features of albinism and formed the 'control' cohort. We note that in-depth ophthalmic phenotyping
291	was not routinely undertaken in Genomics England 100,000 Genomes Project participants. Thus, we
292	cannot be certain that a small number of individuals with mild/subclinical forms of albinism are not
293	included in the control cohort.
294	
295	
296	Identifying functional regulatory and protein-coding variants
297	Regulatory variants: Focusing on TYR, we identified changes that are likely to have an impact on
298	gene regulation by selecting variants that:
299	• are known <i>TYR</i> eQTLs.
300 301	• alter <i>TYR</i> cis-regulatory elements, including the promoter of the gene.
302	To identify eQTLs, we inspected the eQTL catalogue ⁴⁷ and used data from the Genotype-Tissue
303	Expression v8 (GTEx) ⁴⁸ and Eye Genotype Expression (EyeGEx) ⁴⁹ projects. To identify regulatory
304	elements, we used the ENCODE 3 (ENCyclopedia Of DNA Elements phase 3) dataset; the SCREEN
305	(Search Candidate cis-Regulatory Elements by ENCODE) v10 interface was utilised to query this
306	resource for regions flagged as candidate cis-regulatory elements (see
307	https://screen.encodeproject.org/ for further information and definitions). ²⁸ Additional putative
308	regulatory elements were identified by inspecting chromatin accessibility peaks in RPE samples in
309	DESCARTES (the Developmental Single Cell Atlas of Gene Regulation and Expression) ⁵⁰ and through
310	an extensive search of the biomedical literature (e.g. ²⁹). All these queries were conducted in January
311	2021.
312	

- 313 Common protein-coding variants: Focusing on TYR, we identified common changes that are likely to
- 314 have an impact on protein function by selecting variants that:
- have a CADD PHRED-scaled score ≥20. CADD is a widely-used integrative annotation tool built
- from more than 60 genomic features. A PHRED-scaled score ≥10 indicates a raw score in the
- 317 top 10% of all possible single nucleotide variants, while a score ≥ 20 indicates a raw score in the
- top 1%;²² it is noted that a cut-off of 20 has balanced sensitivity and specificity (90% and 69%
- 319 respectively)⁵¹ in the context of this non-diagnostic setting.
- alter protein-coding sequences including missense changes, nonsense variants and small
- 321 insertions/deletions; variants with a potential role on splicing (e.g. synonymous changes and
- 322 variants altering splice donor/acceptor sites) were not included.
- 323 have "total" MAF ≥1% in gnomAD v2.1.1²⁷
- 324
- 325 <u>Rare protein-coding variants</u>: Focusing on 19 albinism-related genes (TYR, OCA2, TYRP1, SLC45A2,
- 326 SLC24A5, C10ORF11, GPR143, HPS 1 to 10, LYST, SLC38A8), we identified rare changes that are
- 327 likely to have an impact on protein function by selecting variants that:
- are labelled as disease-causing (DM) in HGMD v2021.2.
- are included in the following HGMD v2021.2 "mutation type" categories: missense/nonsense,
- 330 splicing, small deletions, small insertions or small indels; gross deletions, gross
- insertions/duplications and complex rearrangements were not analysed.
- have "total" MAF <1% in gnomAD v2.1.1²⁷.
- 333
- 334

335 Case-control analysis to estimate albinism risk

336 The effect of homozygosity for selected *TYR* haplotypes (formed by one common regulatory change,

- 337 c.-301C>T, and two common protein-coding variants, c.575C>A and c.1205G>A variants) on
- 338 albinism risk (i.e. the probability of receiving a diagnosis of albinism) was estimated using data from
- the University Hospital of Bordeaux albinism cohort and the Genomics England 100,000 Genomes
- 340 Project dataset. A case-control analysis of a binary trait (presence/absence of albinism) was
- 341 conducted assuming a recessive model. Logistic regression using Firth's bias reduction method^{31,32}

342 was utilised (as implemented in "logistf" R package)⁵⁰. The following covariates were included:

343 gender, number of rare HGMD-listed variants and ancestry (Supplementary Table 3).

344

345 Although ancestry was included as a co-variate in our logistic regression model, this analysis was 346 imperfect as it was not possible to objectively determine genetic ancestry in the University Hospital 347 of Bordeaux albinism cohort (as mentioned above, self-identified ethnicity was instead used as a 348 surrogate). Confounding by ancestry (i.e population stratification) is therefore a possibility. This can 349 arise if there are systematic differences in ancestral background between cases and controls; these 350 differences can result in significantly different allele/genotype frequencies between the compared 351 groups that may lead to spurious association signals.⁵² We attempted to quantify the bias in our data 352 by calculating the genomic inflation factor lambda (λ GC). λ GC is conceptually simple and involves 353 using a set of random genetic markers to quantitatively estimate the structural differences between 354 the case and control populations.^{38,39} The selected λ GC markers have to be unlinked and should not 355 be expected to show an association with the trait under study (albinism or skin pigmentation in this 356 case). We therefore selected 35 single-nucleotide variants that (i) had a CADD PHRED-scaled score 357 <5 (i.e. were unlikely to be functionally relevant) and (ii) were genotyped both by the gene panels 358 used in the University Hospital of Bordeaux albinism cohort and the genome sequencing assays 359 used in Genomics England 100,000 Genomes Project participants (Supplementary Table 7). 360 Subsequently, case-control comparisons were made for each of these 35 λ GC markers using Firth 361 regression analysis. The resulting test statistics were then used to calculate the median value of 362 λGC.

363

364 To further understand the impact of recent ancestry on our results, we analysed selected subsets of 365 the case and control cohorts. First, we performed sub-analysis of the Genomics England 100,000 366 Genomes Project cases (n=105) and controls (n=29,497). Then we aimed to compare groups that 367 were matched both in terms of genetic ancestry and geographical origin; thus we focused on the 368 Genomics England 100,000 Genomes Project cases (n=76) and controls (n=22,927) that have 369 European ancestries (as inferred by principal component analysis). Finally, we repeated our primary 370 analysis using individuals from both the University Hospital of Bordeaux and the Genomics England 371 100,000 Genomes Project cohorts but this time focusing only on the cases (n=1,107) and controls

372 (n=22,927) that have European ancestries. The results are shown in Supplementary Figure 3 and
 373 Supplementary Tables 8-10.

374

375 Analysis of visual acuity and foveal thickness in UK Biobank participants

376 The effect of homozygosity for selected TYR haplotypes was studied in UK Biobank participants. UK 377 Biobank is a biomedical resource containing in-depth genetic and health information from >500,000 378 individuals from across the UK¹². A subset of UK Biobank volunteers underwent enhanced 379 phenotyping including visual acuity testing (131,985 individuals) and imaging of the central retina 380 (84,748 individuals)⁵³; the latter was obtained using optical coherence tomography (OCT), a non-381 invasive imaging test that rapidly generates cross-sectional retinal scans at micrometre-resolution.⁵⁴ 382 All UK Biobank volunteers analysed as part of this study were imaged using the 3D OCT-1000 Mark 383 II device (Topcon, Japan); the relevant methodology has been previously described.⁵³ Notably, only 384 24 UK Biobank participants are assigned a diagnosis of albinism (data field 41270; ICD-10 term 385 "Albinism" [E70.3]) of which only 7 had visual acuity measurements and none had OCT imaging; 19 386 additional individuals had a diagnosis of albinism in their primary care record data (resource 591). 387 Given that reduced visual acuity and increased central retinal thickness (due to underdevelopment of 388 the fovea) are two key hallmark features of albinism we investigated the impact of TYR risk 389 haplotypes on these quantitative endophenotypes. 390 391 First, genotyping array data were used to obtain genotypes for TYR c.575C>A [rs1042602] and TYR 392 c.1205G>A [rs1126809] (data field 22418 including information from the Applied Biosystems UK 393 Biobank Axiom Array containing 825,927 markers). In contrast to these two changes, the TYR 394 c.-301C>T [rs4547091] variant was not directly captured by the array. However, high-quality 395 (>99.9%) imputation data on this promoter change were available (data field 22828). 396 397 Subsequently, we calculated the mean of the right and left LogMAR visual acuity for each UK 398 Biobank volunteer (data fields 5201 and 5208, "instance 0" datasets). These visual acuity 399 measurements were subsequently used to compare visual performance between groups of people 400 with different homozygous haplotype combinations. As the obtained distributions deviated from

401 normality (Fig.2C), the Kruskal-Wallis test was used. Pair-wise comparisons were performed and the 402 p-values were adjusted using the Benjamini-Hochberg method (Supplementary Table 5). 403 404 To obtain central foveal thickness measurements from UK Biobank OCT images, we calculated the 405 mean of the right and left central retinal thickness (defined as the average distance between the 406 hyperreflective bands corresponding to the RPE and the internal limiting membrane (ILM), across the central 1 mm diameter circle of the ETDRS grid) for each UK Biobank volunteer).⁵¹ The obtained 407 408 measurements were then subsequently used to compare central macular thickness between groups 409 of UK Biobank volunteers with different homozygous TYR haplotype combinations. As some of the 410 obtained distributions deviated from normality (Supplementary Fig.2), the Kruskal-Wallis test was 411 used. Pair-wise comparisons were performed and the p-values were adjusted using the Benjamini-412 Hochberg method (Supplementary Table 6). 413 414 DATA AND CODE AVAILABILITY STATEMENT 415 416 Genomics England 100,000 Genomes Project data are available through an access 417 418 procedure described at https://www.genomicsengland.co.uk/about-gecip/forgecip-members/data-and-data-access. UK Biobank data are available through a 419 420 procedure described at http://www.ukbiobank.ac.uk/using-the-resource/. All other 421 data supporting the findings of this study are available within the article (including 422 its supplementary information files) or from the authors upon request. The scripts

- 423 used to analyse the datasets included in this study can be found
- 424 at https://github.com/davidjohngreen.

ACKNOWLEDGEMENTS 426

- 427
- 428 We acknowledge the following sources of funding: the Wellcome Trust
- 429 (200990/Z/16/Z, Transforming Genetic Medicine Initiative); Christopher Green;
- 430 Retina UK and Fight for Sight (GR586, RP Genome Project - UK Inherited Retinal
- Disease Consortium); Health Education England; UK National Institute for Health 431
- 432 Research (NIHR) Clinical Lecturer Programme (CL-2017-06-001); the French
- 433 Albinism Association (Genespoir).
- 434

435 This research was made possible through access to the data and findings

436 generated by the 100,000 Genomes Project. The 100,000 Genomes Project is

437 managed by Genomics England Limited (a wholly owned company of the

438 Department of Health and Social Care). The 100,000 Genomes Project is funded by

439 the National Institute for Health Research and NHS England. The Wellcome Trust,

440 Cancer Research UK and the Medical Research Council have also funded research

441 infrastructure. The 100,000 Genomes Project uses data provided by patients and

442 collected by the National Health Service as part of their care and support.

443

444 We acknowledge the contribution of the Genomics England Research Consortium 445 to the 100,000 Genomes Project. Members of this Consortium include: John C. Ambrose, Prabhu Arumugam, Roel Bevers, Marta Bleda, Freya Boardman-Pretty, 446 447 Christopher R. Boustred, Helen Brittain, Mark J. Caulfield, Georgia C. Chan, Greg Elgar, Tom Fowler, Adam Giess, Angela Hamblin, Shirley Henderson, Tim J. P. 448 449 Hubbard, Rob Jackson, Louise J. Jones, Dalia Kasperaviciute, Melis Kayikci, 450 Athanasios Kousathanas, Lea Lahnstein, Sarah E. A. Leigh, Ivonne U. S. Leong,

451	Javier F. Lopez, Fiona Maleady-Crowe, Meriel McEntagart, Federico Minneci,
452	Loukas Moutsianas, Michael Mueller, Nirupa Murugaesu, Anna C. Need, Peter
453	O'Donovan, Chris A. Odhams, Christine Patch, Mariana Buongermino Pereira,
454	Daniel Perez-Gil, John Pullinger, Tahrima Rahim, Augusto Rendon, Tim Rogers,
455	Kevin Savage, Kushmita Sawant, Richard H. Scott, Afshan Siddiq, Alexander
456	Sieghart, Samuel C. Smith, Alona Sosinsky, Alexander Stuckey, Mélanie Tanguy,
457	Ana Lisa Taylor Tavares, Ellen R. A. Thomas, Simon R. Thompson, Arianna Tucci,
458	Matthew J. Welland, Eleanor Williams, Katarzyna Witkowska, Suzanne M. Wood
459	
460	This research was conducted using the UK Biobank Resource under projects
461	53144, 49978 and 2112. Members of the UK Biobank Eye and Vision Consortium
462	include: Tariq Aslam, Sarah Barman, Jenny Barrett, Paul Bishop, Catey Bunce,
463	Roxana Carare, Usha Chakravarthy, Michelle Chan, Valentina Cipriani, Alexander
464	Day, Parul Desai, Bal Dhillon, Andrew Dick, Cathy Egan, Sarah Ennis, Paul Foster,
465	Marcus Fruttiger, John Gallacher, David Garway-Heath, Jane Gibson, Dan Gore,
466	Jeremy Guggenheim, Chris Hammond, Alison Hardcastle, Simon Harding, Ruth
467	Hogg, Pirro Hysi, Pearse A. Keane, Peng T. Khaw, Anthony Khawaja, Gerassimos
468	Lascaratos, Andrew J. Lotery, Phil Luthert, Tom Macgillivray, Sarah Mackie,
469	Bernadette Mcguinness, Gareth Mckay, Martin Mckibbin, Danny Mitry, Tony Moore,
470	James Morgan, Zaynah Muthy, Eoin O'Sullivan, Chris Owen, Praveen Patel, Euan
471	Paterson, Tunde Peto, Axel Petzold, Jugnoo Rahi, Alicja Rudnicka, Jay Self, Sobha
472	Sivaprasad, David Steel, Irene Stratton, Nicholas Strouthidis, Cathie Sudlow,
473	Caroline Thaung, Dhanes Thomas, Emanuele Trucco, Adnan Tufail, Veronique Vitart,
474	Stephen Vernon, Ananth Viswanathan, Cathy Williams, Katie Williams, Jayne
475	Woodside, Max Yates, Jennifer Yip, Yalin Zheng, Robyn Tapp, Denize Atan,

- 476 Alexander Doney, Naomi Allen, Thomas Littlejohns, Panagiotis Sergouniotis,
- 477 Graeme Black.
- 478
- 479 Lastly, we acknowledge the help of Cécile Courdier at the University Hospital of
- 480 Bordeaux Molecular Genetics Laboratory and of Jamie Ellingford at the University of
- 481 Manchester.
- 482

483 COMPETING INTERESTS STATEMENT

- 484
- 485 E.B. is a paid consultant and equity holder of Oxford Nanopore, a paid consultant to
- 486 Dovetail, and a non-executive director of Genomics England, a limited company
- 487 wholly owned by the UK Department of Health and Social Care. All other authors
- 488 declare no competing interests.

489

491 REFERENCES

- 493 1. Claussnitzer, M. et al. A brief history of human disease genetics. Nature 577, 179–189 (2020).
- 494 2. Shendure, J., Findlay, G. M. & Snyder, M. W. Genomic Medicine-Progress, Pitfalls, and 495 Promise. Cell 177, 45-57 (2019).
- 496 3. Niemi, M. E. K. et al. Common genetic variants contribute to risk of rare severe 497 neurodevelopmental disorders. Nature 562, 268-271 (2018).
- 498 4. Tilghman, J. M. et al. Molecular genetic anatomy and risk profile of Hirschsprung's disease. 499 N. Engl. J. Med. 380, 1421-1432 (2019).
- 500 5. Turro, E. et al. Whole-genome sequencing of patients with rare diseases in a nationalhealth 501 system. Nature 583, 96 (2020).
- 502 6. Chung, B. H. Y., Chau, J. F. T. & Wong, G. K.-S. Rare versus common diseases: a false 503 dichotomy in precision medicine. NPJ genomic Med. 6, (2021).
- 504 7. Khan, M. et al. Resolving the dark matter of ABCA4 for 1054 Stargardt disease probands 505 through integrated genomics and transcriptomics. Genet. Med. 22, 1235-1246 (2020).
- 506 8. Harper, A. R. et al. Common genetic variants and modifiable risk factors underpin 507 hypertrophic cardiomyopathy susceptibility and expressivity. Nat. Genet. 2021 532 53, 135-508 142 (2021).
- 509 9. Boycott, K. M. et al. International cooperation to enable the diagnosis of all rare genetic 510 diseases. Am. J. Hum. Genet. 100, 695 (2017).
- 511 10. Ferreira, C. R. The burden of rare diseases. Am. J. Med. Genet. A 179, 885–892 (2019).
- 512 11. Chakravarti, A. Magnitude of Mendelian versus complex inheritance of rare disorders. Am. J. 513 Med. Genet. A (2021). doi:10.1002/AJMG.A.62463
- 514 12. Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 515 **562**, 203–209 (2018).
- 516 13. Genomics England. The National Genomic Research Library v5.1. (2019). Available at: 517 https://doi.org/10.6084/m9.figshare.4530893.v6.
- 518 14. Kruijt, C. C. et al. The phenotypic spectrum of albinism. Ophthalmology 125, 1953–1960 519 (2018).
- 520 Farabee, W. C. Notes on Negro Albinism. Science 17, 75 (1903). 15.
- 521 16. Garrod, A. E. The Croonian Lectures on Inborn Errors of Metabolism. Lancet 172, 1-7 (1908).
- 522 17. Lasseaux, E. et al. Molecular characterization of a series of 990 index patients with albinism. 523 Pigment Cell Melanoma Res. 31, 466-474 (2018).
- 524 18. Wang, C. et al. [Spectrum of pathological genetic variants among 405 Chinese pedigrees 525 affected with oculocutaneous albinism]. Chin J Med Genet 37, 725-730 (2020).
- 526 19. Mauri, L. et al. Clinical evaluation and molecular screening of a large consecutive series of 527 albino patients. J. Hum. Genet. 62, 277-290 (2017).

- 528 20. Pavan, W. J. & Sturm, R. A. The genetics of human skin and hair pigmentation. Annu. Rev. 529 Genomics Hum. Genet. 20, 41–72 (2019).
- 530 21. Campbell, P. et al. Clinical and genetic variability in children with partial albinism. Sci. Rep. 9, 531 16576 (2019).
- 532 22. Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: Predicting the 533 deleteriousness of variants throughout the human genome. Nucleic Acids Res. 47. D886-534 D894 (2019).
- 535 Buniello, A. et al. The NHGRI-EBI GWAS Catalog of published genome-wide association 23. 536 studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 47, D1005 (2019).
- 537 24. Chaki, M. et al. Molecular and functional studies of tyrosinase variants among Indian 538 oculocutaneous albinism type 1 patients. J. Invest. Dermatol. 131, 260-262 (2011).
- 539 25. Jagirdar, K. et al. Molecular analysis of common polymorphisms within the human Tyrosinase 540 locus and genetic association with pigmentation traits. Pigment Cell Melanoma Res. 27, 552-541 564 (2014).
- 542 26. Monfermé, S. et al. Mild form of oculocutaneous albinism type 1: phenotypic analysis of 543 compound heterozygous patients with the R402Q variant of the TYR gene. Br. J. Ophthalmol. 544 **103**, 1239–1247 (2019).
- 545 27. Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 546 141,456 humans. Nature 581, 434-443 (2020).
- 547 28. The ENCODE Project Consortium et al. Expanded encyclopaedias of DNA elements in the 548 human and mouse genomes. Nature 583, 699-710 (2020).
- 549 29. Liu, B. et al. Genetic analyses of human fetal retinal pigment epithelium gene expression 550 suggest ocular disease mechanisms. Commun. Biol. 2, 186 (2019).
- 551 30. Reinisalo, M., Putula, J., Mannermaa, E., Urtti, A. & Honkakoski, P. Regulation of the human 552 tyrosinase gene in retinal pigment epithelium cells: The significance of transcription factor 553 orthodenticle homeobox 2 and its polymorphic binding site. Mol. Vis. 18, 38-54 (2012).
- 554 31. Heinze, G. & Schemper, M. A solution to the problem of separation in logistic regression. Stat. 555 Med. 21, 2409-2419 (2002).
- 556 32. Firth, D. Bias Reduction of Maximum Likelihood Estimates. *Biometrika* 80, 27 (1993).
- 557 33. Castel, S. E. et al. Modified penetrance of coding variants by cis-regulatory variation 558 contributes to disease risk. Nat. Genet. 50, 1327 (2018).
- 559 34. Auton, A. et al. A global reference for human genetic variation. Nat. 2015 5267571 526, 68-74 560 (2015).
- 561 35. Mason, C. & Guillery, R. Conversations with Ray Guillery on albinism: linking Siamese cat 562 visual pathway connectivity to mouse retinal development. Eur. J. Neurosci. 49, 913-927 563 (2019).
- 564 36. Stenson, P. D. et al. The Human Gene Mutation Database (HGMD ®): optimizing its use in a 565 clinical diagnostic or research setting. Hum. Genet. 139, 1197-1207 (2020).
- 566 37. Freedman, M. L. et al. Assessing the impact of population stratification on genetic association 567 studies. Nat. Genet. 2004 364 36, 388-393 (2004).

- 568 38. Devlin, B. & Roeder, K. Genomic control for association studies. *Biometrics* **55**, 997–1004 (1999).
- 570 39. Dadd, T., Weale, M. E. & Lewis, C. M. A critical evaluation of genomic control methods for genetic association studies. *Genet. Epidemiol.* **33**, 290–298 (2009).
- 57240.Richards, S. *et al.* Standards and guidelines for the interpretation of sequence variants: a joint573consensus recommendation of the American College of Medical Genetics and Genomics and574the Association for Molecular Pathology. *Genet. Med. 2015* 175 17, 405–423 (2015).
- 575 41. Turnbull, C. *et al.* The 100 000 Genomes Project: bringing whole genome sequencing to the NHS. *BMJ* **361**, 1687 (2018).
- 577 42. Köhler, S. *et al.* The Human Phenotype Ontology in 2021. *Nucleic Acids Res.* 49, D1207–
 578 D1217 (2021).
- 57943.Raczy, C. *et al.* Isaac: ultra-fast whole-genome secondary analysis on Illumina sequencing580platforms. *Bioinformatics* **29**, 2041–2043 (2013).
- 581 44. Tan, A., Abecasis, G. R. & Kang, H. M. Unified representation of genetic variants.
 582 *Bioinformatics* **31**, 2202–2204 (2015).
- 583 45. Danecek, P. *et al.* Twelve years of SAMtools and BCFtools. *Gigascience* **10**, giab008 (2021).
- 584 46. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, (2016).
- 58547.Nurlan, K. *et al.* A compendium of uniformly processed human gene expression and splicing586quantitative trait loci. *Nat. Genet.* **53**, 1290–1299 (2021).
- 58748.The GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across588human tissues. Science 369, 1318–1330 (2020).
- 58949.Ratnapriya, R. *et al.* Retinal transcriptome and eQTL analyses identify genes associated with590age-related macular degeneration. *Nat. Genet.* **51**, 606–610 (2019).
- 591 50. Domcke, S. *et al.* A human cell atlas of fetal chromatin accessibility. *Science* **370**, (2020).
- 592 51. van der Velde, K. J. *et al.* GAVIN: Gene-Aware Variant INterpretation for medical sequencing.
 593 *Genome Biol.* 18, 1–10 (2017).
- 594 52. Marchini, J., Cardon, L. R., Phillips, M. S. & Donnelly, P. The effects of human population 595 structure on large genetic association studies. *Nat. Genet. 2004 365* **36**, 512–517 (2004).
- 596 53. Chua, S. Y. L. *et al.* Cohort profile: design and methods in the eye and vision consortium of UK Biobank. *BMJ Open* **9**, e025077 (2019).
- 59854.Drexler, W. & Fujimoto, J. G. State-of-the-art retinal optical coherence tomography. Prog.599Retin. Eye Res. 27, 45–88 (2008).
- 60055.Currant, H. *et al.* Genetic variation affects morphological retinal phenotypes extracted from601UK Biobank optical coherence tomography images. *PLoS Genet.* **17**, e1009497 (2021).
- 602

603 TABLE

604

Table 1. Contribution of different classes of albinism-related variants to disease risk

combination of common ^a and rare ^b risk genotypes	odds ratio °	95% confidence interval	p-value
6 common + 0 rare	391	165 - 982	0.000016
5 common + 0 rare	7.8	3.6 - 16.5	<0.00001
4 common + 0 rare	3.4	1.9 – 6.1	0.000014
3 common + 0 rare	1.5	0.8 - 2.6	0.17
2 common + 0 rare	2.3	1.3 - 4	0.002
1 common + 0 rare	1.1	0.6 - 1.9	0.84
0 common + 0 rare	0.1	0.1 - 0.2	<0.00001
6 common + 1 rare ^d	217	26.7 - 2519	0.00001
5 common + 1 rare	302	156 - 566	<0.00001
4 common + 1 rare	38	22 - 69	<0.00001
3 common + 1 rare	8.7	4.9 - 15.6	<0.00001
2 common + 1 rare	7.5	4.2 - 13.5	<0.00001
1 common + 1 rare	6	3.2 - 11.2	<0.00001
0 common + 1 rare	2.6	1.2 - 5.3	0.016
0 common + 2 rare	163	75 - 367	<0.00001
6 common + 1 rare TYR d	120	6 - 17919	0.003
5 common + 1 rare TYR	178	82 - 425	<0.00001
4 common + 1 rare TYR	38.6	20 - 80	<0.00001
3 common + 1 rare TYR	5.3	2.6 – 11	<0.00001
2 common + 1 rare TYR	2.4	1.2 – 5.4	0.02
1 common + 1 rare TYR d	0.6	0.2 – 1.9	0.43
0 common + 1 rare TYR d	2.3	0.4 – 8	0.28
0 common + 2 rare TYR d	446	100 - 4270	<0.00001

^a presence of each of the following TYR variants in heterozygous state was considered as one common risk genotype: c.-301C [rs4547091]; c.575C>A (p.Ser192Tyr) [rs1042602]; c.1205G>A (p.Arg402Gln) [rs1126809]. TYR variant numbering is based on the transcript with the following identifiers: NM 000372.5 and ENST00000263321.6.

^b autosomal albinism-related genes were inspected and each heterozygous protein-coding change with a minor-allele frequency <1% and a "disease-causing" (DM) label in the Human Gene Mutation Database (HGMD) v2021.2 was considered as one rare risk genotype. Such genotypes in the TYR gene are labelled "rare TYR".

^c Firth regression analysis with gender and ancestry as covariates was used to estimate odds ratios and p-values; 1,121 probands with albinism and 29,453 unrelated controls were included (Supplementary Table 1).

^d Less than 10 individuals were included in the smallest subgroup of these categories, reducing the reliability of the associated findings.